Clinical Impact of New Data From HIVR4P 2021 Virtual

January 27-28 and February 3-4, 2021
In this downloadable slideset, CCO’s expert faculty members summarize key studies from this important conference, including clinical data on new PrEP options, implementation strategies, multipurpose prevention technologies, and an emerging treatment.
Linda-Gail Bekker, MBChB, DTM&H, DCH, FCP(SA), PhD
Kenneth Mayer, MD
Format: Microsoft PowerPoint (.ppt)
File Size: 518 KB
Released: February 17, 2021

Acknowledgements

Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Produced in collaboration with
Educational grant provided by:
Gilead Sciences, Inc.
Janssen Therapeutics, Division of Janssen Products, LP
Merck Sharp & Dohme Corp.
ViiV Healthcare

Related Content

Clinical Care Options’ (CCO) commentary from a person with HIV on what it was like living through the COVID-19 pandemic as a long-term HIV survivor

person default Frank Primavera Released: June 9, 2021

Latesha Elopre and CCO: starting HIV pre-exposure prophylaxis (PrEP). DISCOVER study, CDC guidance, racial/ethnic disparities, overcoming barriers

Latesha Elopre, MD, MSPH Released: June 7, 2021

Slides from CCO: Switching ART in HIV: 3-drug therapy, oral 2-drug options, long-acting injectable 2-drug regimens, single tablet regimens (STRs)

Daniel R. Kuritzkes, MD Chloe Orkin Photo Chloe Orkin, MBChB, FRCP, MD Released: June 7, 2021

Slides from Latesha Elopre and CCO: starting HIV preexposure prophylaxis (PrEP). DISCOVER study, CDC guidance, racial/ethnic disparities, overcoming barriers.

Latesha Elopre, MD, MSPH Released: June 7, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue